The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior …
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors …
Published: 11/15/2024